ArticleNeuro-ophthalmology (Aeolus Press)2025
Venous Sinus Stenting Outcomes in Patients with Papilledema from Secondary Causes of Elevated Intracranial Pressure.
Article in Neuro-ophthalmology (Aeolus Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Venous sinus stenting (VSS) has recently emerged as a promising intervention in patients with idiopathic intracranial hypertension (IIH) who fail medical therapy. Less is known on outcomes of VSS to manage papilledema from secondary causes of increased intracranial pressures (ICP), such as venous sinus thrombosis. A retrospective cohort study was conducted to evaluate the outcomes of VSS for four patients with papilledema from secondary causes of elevated ICP. A subset of 25 consecutive IIH patients with equivalent degrees of papilledema who underwent VSS served as a comparison group. Of the four patients with secondary causes of papilledema, three had increased ICP due to venous sinus thrombosis and one following surgical treatment of a spinal CSF-venous fistula. The median papilledema grade in patients with secondary causes of elevated ICP was 3.75 (range 3-4) at baseline, with only one (25%) having a significant sustained improvement in papilledema after VSS (overall post-stent median papilledema grade 2.5, range 0-3.5). In comparison, all 25 patients with IIH and grade ≥3 papilledema at baseline (median 4, range 3-5) had improvement of papilledema at least to grade 1 (median 1, range 0-1) at 3-month follow-up (p=0.003 for secondary causes vs IIH). Three (75%) patients with secondary causes of elevated ICP and four (16%) IIH patients required additional procedures for residual raised intracranial pressure after initial VSS (p=0.034). This study suggests that secondary causes of raised ICP may respond less to VSS than IIH patients with similar degrees of papilledema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.